awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q40143100-FEB92E58-D773-4BF9-A3F4-ABB222D73C78
Q40143100-FEB92E58-D773-4BF9-A3F4-ABB222D73C78
BestRank
Statement
http://www.wikidata.org/entity/statement/Q40143100-FEB92E58-D773-4BF9-A3F4-ABB222D73C78
Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.
P2860
Q40143100-FEB92E58-D773-4BF9-A3F4-ABB222D73C78
BestRank
Statement
http://www.wikidata.org/entity/statement/Q40143100-FEB92E58-D773-4BF9-A3F4-ABB222D73C78
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
76a6e005b539e9f567a464386b93fdd1f71316a9
P2860
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week res